Campath alemtuzumab: Phase III data

In the open-label, international Phase III CAM307 trial in 297 treatment-naïve patients, Campath

Read the full 139 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE